US Active Pharmaceutical Ingredients Market Insights Forecasts to 2033

• The US Active Pharmaceutical Ingredients Market Size was valued at USD 82.3 Billion in 2023.
• The Market Size is Growing at a CAGR of 4.31 % from 2023 to 2033
• The US Active Pharmaceutical Ingredients Market Size is expected to reach USD 125.5 Billion by 2033

US Active Pharmaceutical Ingredients Market is anticipated to exceed USD 125.5 Billion by 2033, growing at a CAGR of 4.31 % from 2023 to 2033.

Market Overview

 Active pharmaceutical ingredients are the main ingredient of a medication that gives it the intended effect. Several active pharmacological ingredients that have distinct physiological effects are present in several medications. Also known as pharmacologic substance, drug substance, and API. APIs are available in a variety of dosage forms, including tablets, capsules, and injections, and can be artificially produced or sourced from natural sources. APIs interact with the body to provide the intended therapeutic effect after they are swallowed or delivered. To guarantee the security and effectiveness of pharmaceutical medicines, they go through strict quality control procedures. The demand for APIs has significantly increased due to the growing need for ecologically friendly production methods and growing awareness of the ecological concerns connected with older chemical pathways. In addition, there has been a significant increase in innovators and CDMOs in the nation, which is expected to fuel market expansion there.

Report Coverage

This research report categorizes the market for the US active pharmaceutical ingredients market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the active pharmaceutical ingredients market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the active pharmaceutical ingredients market.

Driving Factors

The increasing incidence of infectious diseases, genetic problems, and chronic illnesses is driving up demand for active pharmaceutical ingredients, or APIs. Furthermore, the demand for safe and effective medications to address these illnesses is what's causing the increase in demand. Moreover, the growing number of people with diabetes is putting more emphasis on developing sophisticated, safe medications, requiring a significant quantity of API and accelerating market expansion. Additionally, it is anticipated that physicians and patients will adopt more biosimilar and biologics due to their growing expansion and success in medical trials, as well as the growing acceptance of novel therapeutic classes. This will enhance demand for APIs and propel market development.

Restraining Factors

The Active Pharmaceutical Ingredients (APIs) market encounters significant difficulties due to pricing pressure from competitors offering generic APIs. Furthermore, natural disasters, geopolitical unrest, and environmental restrictions are a few examples of the variables that might affect raw material availability. Therefore, a major barrier to the expansion of the active pharmaceutical ingredient (API) market is the restricted supply of raw materials.

Market Segmentation

The US active pharmaceutical ingredients market share is classified into types of synthesis and types of manufacturer.

• The synthetic segment is expected to hold the largest market share through the forecast period.   

The US active pharmaceutical ingredients market is segmented by types of synthesis into biotech and synthetic. Among these, the synthetic segment is expected to hold the largest market share through the forecast period. The rising incidence of chronic illnesses including diabetes, cancer, and cardiovascular problems has been proposed to be the cause for this increase in demand for efficient drugs that significantly rely on synthetic APIs. Moreover, the market's synthetic API segment is expanding due to the growing use of biologics and biosimilars as well as developments in cancer medication research.

• The captive segment dominates the market with the largest market share over the predicted period.

The US active pharmaceutical ingredients market is segmented by types of manufacturer into captive and merchant. Among these, the captive segment dominates the market with the largest market share over the predicted period. This increase is ascribed to the growing need for high-quality APIs, the requirement for efficient and economical manufacturing processes, and the growing emphasis on R&D. The country also boasts a booming pharmaceutical sector, with many companies investing in API manufacturing plants, which fuels the expansion of captive API.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the US active pharmaceutical ingredients market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• AbbVie Inc.
• Pfizer Inc. (Pfizer Center One)
• Amgen Inc.
• Viatris Inc.
• Bristol-Myers Squibb Company
• Fresenius Kabi AG.
• Catalent, Inc.
• Curia.
• Ampac Fine Chemicals (AFC)
• Johnson & Johnson

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In April 2023, the FDA approved QULIPTA (atogepant), a novel oral drug that AbbVie developed to stop adult migraine attacks. With this achievement, QULIPTA is now the only CGRP receptor antagonist that may be taken orally to treat both episodic and chronic migraine.

Market Segment

This study forecasts revenue at US, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the US Active Pharmaceutical Ingredients Market based on the below-mentioned segments:

US Active Pharmaceutical Ingredients Market, By Types of Synthesis

• Biotech
• Synthetic

US Active Pharmaceutical Ingredients Market, By Types of Manufacturer

• Captive
• Merchant